We are now in the 'era of human data,' a transformative opportunity for drug discovery and development. Going well beyond genetics, human data includes significant advances in computational techniques and multi-omics, which includes genomics, transcriptomics, and proteomics, plus a tsunami of real world data and real world evidence from electronic health records, insurance claims data bases and many other sources. Insights from human data will help us improve understanding of disease prediction, identify new targets, as well as find the right patient populations for the next generation of first-in-class therapeutics.

How do we use human data when developing drugs?

Human data can help us identify biomarkers to better track disease prediction and progression, as well as improve clinical trials by finding patients who will benefit most from the medicines we are making.

Ray Deshaies
Senior Vice President of Global Research at Amgen


Human Data Podcast

Human Data Era & DNA Unlocked

Hosted by Ray Deshaies

Senior Vice President, Global Drug Development at Amgen

In these series, Ray Deshaies, senior vice president of Global Research at Amgen, together with other scientific experts explore the important transitional point we're now at in the use of human data for drug R&D. What are we really talking about when we talk about human data? How much data do we need? What have we learned so far about human diversity, and why should we continue studying it?  How much closer are we to fully leveraging the human genome and human data to accelerate drug discovery and development and transform personalized medicine for challenging diseases from a goal to reality? 

Listen to Human Data Era    Listen to DNA Unlocked

There's a place for you

We are focused on bringing forward the next generation of first-in-class and best-in-class therapeutics with a large effect size in diseases of high unmet need. With human data, Amgen may be able to predict, in a way that wasn't possible before, how a patient's disease is going to evolve. We'll also identify new biomarkers to estimate which patient populations have the highest risk of developing the disease being targeted and who will benefit most from drugs in development. Join us! We have earned numerous recognitions as a great place to work, including being named one of America's Best Large Employers by Forbes magazine, as well as one of the World's 25 Best Workplaces™ by Fortune and Great Place to Work®.